+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer



Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer



Oncoimmunology 1(3): 326-333



CD4(+)CD25(+)Foxp3(+) regulatory T cells (Treg) have emerged as a dominant T cell population inhibiting anti-tumor effector T cells. Initial strategies used for Treg-depletion (cyclophosphamide, anti-CD25 mAb…) also targeted activated T cells, as they share many phenotypic markers. Current, ameliorated approaches to inhibit Treg aim to either block their function or their migration to lymph nodes and the tumor microenvironment. Various drugs originally developed for other therapeutic indications (anti-angiogenic molecules, tyrosine kinase inhibitors,etc) have recently been discovered to inhibit Treg. These approaches are expected to be rapidly translated to clinical applications for therapeutic use in combination with immunomodulators.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052269756

Download citation: RISBibTeXText

PMID: 22737608

DOI: 10.4161/onci.18852


Related references

Monitoring the frequency and function of regulatory T cells and summary of the approaches currently used to inhibit regulatory T cells in cancer patients. Methods in Molecular Biology 1139: 201-221, 2014

Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: A comprehensive review. International Journal of Pharmaceutics, 2018

Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease. Journal of Virology 85(3): 1287-1297, 2011

Current Perspectives on Novel Drug Delivery Systems and Approaches for Management of Cervical Cancer: A Comprehensive Review. Current Drug Targets 17(3): 337-352, 2016

Holding unregistered health practitioners to account: an analysis of current regulatory and legislative approaches. Journal of Law and Medicine 22(2): 350-375, 2015

iPSC-Derived Regulatory Dendritic Cells Inhibit Allograft Rejection by Generating Alloantigen-Specific Regulatory T Cells. Stem Cell Reports 8(5): 1174-1189, 2017

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunology, ImmunoTherapy 58(7): 1033-1045, 2008

Upper G.I. cancer: the esophagus and stomach. II. The current status of comprehensive gene analysis of esophageal cancer. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 36(9): 1435-1441, 2009

Comprehensive Dissection of Transcriptome Data and Regulatory Factors in Pancreatic Cancer Cells. Journal of Cellular Biochemistry 118(11): 3976-3985, 2017

Comprehensive analysis of the regulatory roles of auxin in early transdifferentiation into xylem cells. Plant Molecular Biology 70(4): 457-469, 2009

Regulatory T Cells from Colon Cancer Patients Inhibit Effector T-cell Migration through an Adenosine-Dependent Mechanism. Cancer Immunology Research 4(3): 183-193, 2016

Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. Journal of Immunology 168(9): 4272-4276, 2002

Comprehensive analysis of the long noncoding RNA HOXA11-AS gene interaction regulatory network in NSCLC cells. Cancer Cell International 16: 89-89, 2016

Evaluation of current approaches to inhibit HIV entry. Current Drug Targets. Infectious Disorders 2(1): 9-16, 2002

Proteome analysis of regulatory T cells Promising targets for innovative immunotherapeutical approaches. Molecular & Cellular Proteomics 2(9): 990, September, 2003